Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 498

1.

A Validation Study of Administrative Claims Data to Measure Ovarian Cancer Recurrence and Secondary Debulking Surgery.

Livaudais-Toman J, Egorova N, Franco R, Prasad-Hayes M, Howell EA, Wisnivesky J, Bickell NA.

EGEMS (Wash DC). 2016 Nov 1;4(1):1208.

2.

Suboptimal use of pelvic lymph node dissection: Differences in guideline adherence between robot-assisted and open radical prostatectomy.

Schiffmann J, Larcher A, Sun M, Tian Z, Berdugo J, Leva I, Widmer H, Lattouf JB, Zorn KC, Shariat SF, Montorsi F, Graefen M, Saad F, Karakiewicz PI.

Can Urol Assoc J. 2016 Aug;10(7-8):269-276.

3.

Cost Implications of Comorbidity for Autologous Stem Cell Transplantation in Elderly Patients with Multiple Myeloma Using SEER-Medicare.

Shah GL, Winn A, Lin PJ, Klein A, Sprague KA, Smith HP, Buchsbaum R, Cohen JT, Miller KB, Comenzo R, Parsons SK.

Bone Marrow Res. 2016;2016:3645623.

4.

Long-term health care costs for prostate cancer patients on androgen deprivation therapy.

Krahn MD, Bremner KE, Luo J, Tomlinson G, Alibhai SM.

Curr Oncol. 2016 Oct;23(5):e443-e453.

5.

The impact of chronic conditions on the economic burden of cancer survivorship: a systematic review.

Rim SH, Guy GP Jr, Yabroff KR, McGraw KA, Ekwueme DU.

Expert Rev Pharmacoecon Outcomes Res. 2016 Oct;16(5):579-589.

6.

Associations between cancer and Alzheimer's disease in a U.S. Medicare population.

Freedman DM, Wu J, Chen H, Kuncl RW, Enewold LR, Engels EA, Freedman ND, Pfeiffer RM.

Cancer Med. 2016 Oct;5(10):2965-2976. doi: 10.1002/cam4.850.

7.

Risk prediction and clinical model building for lymph node metastasis in papillary thyroid microcarcinoma.

Lin DZ, Qu N, Shi RL, Lu ZW, Ji QH, Wu WL.

Onco Targets Ther. 2016 Aug 24;9:5307-16. doi: 10.2147/OTT.S107913.

8.

Tumor size interpretation for predicting cervical lymph node metastasis using a differentiated thyroid cancer risk model.

Shi RL, Qu N, Yang SW, Ma B, Lu ZW, Wen D, Sun GH, Wang Y, Ji QH.

Onco Targets Ther. 2016 Aug 12;9:5015-22. doi: 10.2147/OTT.S107187.

9.

Surveillance Practice Patterns after Curative Intent Therapy for Stage I Non-Small-Cell Lung Cancer in the Medicare Population.

Erb CT, Su KW, Soulos PR, Tanoue LT, Gross CP.

Lung Cancer. 2016 Sep;99:200-7. doi: 10.1016/j.lungcan.2016.07.017.

PMID:
27565940
10.

The effect of statins on survival in patients with stage IV lung cancer.

Lin JJ, Ezer N, Sigel K, Mhango G, Wisnivesky JP.

Lung Cancer. 2016 Sep;99:137-42. doi: 10.1016/j.lungcan.2016.07.006.

PMID:
27565929
11.

Association between Metformin Use and Cancer Stage at Diagnosis among Elderly Medicare Beneficiaries with Preexisting Type 2 Diabetes Mellitus and Incident Prostate Cancer.

Raval AD, Mattes MD, Madhavan S, Pan X, Wei W, Sambamoorthi U.

J Diabetes Res. 2016;2016:2656814. doi: 10.1155/2016/2656814.

12.
13.

Age and Prostate-Specific Antigen Level Prior to Diagnosis Predict Risk of Death from Prostate Cancer.

MacKintosh FR, Sprenkle PC, Walter LC, Rawson L, Karnes RJ, Morrell CH, Kattan MW, Nawaf CB, Neville TB.

Front Oncol. 2016 Jun 28;6:157. doi: 10.3389/fonc.2016.00157.

14.

Metformin Improves Survival in Patients with Pancreatic Ductal Adenocarcinoma and Pre-Existing Diabetes: A Propensity Score Analysis.

Amin S, Mhango G, Lin J, Aronson A, Wisnivesky J, Boffetta P, Lucas AL.

Am J Gastroenterol. 2016 Sep;111(9):1350-7. doi: 10.1038/ajg.2016.288.

PMID:
27430290
16.

Prior cancer does not adversely affect survival in locally advanced lung cancer: A national SEER-medicare analysis.

Laccetti AL, Pruitt SL, Xuan L, Halm EA, Gerber DE.

Lung Cancer. 2016 Aug;98:106-13. doi: 10.1016/j.lungcan.2016.05.029.

PMID:
27393515
17.

Bone Morphogenetic Protein Use and Cancer Risk Among Patients Undergoing Lumbar Arthrodesis: A Case-Cohort Study Using the SEER-Medicare Database.

Beachler DC, Yanik EL, Martin BI, Pfeiffer RM, Mirza SK, Deyo RA, Engels EA.

J Bone Joint Surg Am. 2016 Jul 6;98(13):1064-72. doi: 10.2106/JBJS.15.01106.

PMID:
27385679
18.

Anticipating the "Silver Tsunami": Prevalence Trajectories and Comorbidity Burden among Older Cancer Survivors in the United States.

Bluethmann SM, Mariotto AB, Rowland JH.

Cancer Epidemiol Biomarkers Prev. 2016 Jul;25(7):1029-36. doi: 10.1158/1055-9965.EPI-16-0133.

PMID:
27371756
19.

Challenges in translating endpoints from trials to observational cohort studies in oncology.

Ording AG, Cronin-Fenton D, Ehrenstein V, Lash TL, Acquavella J, Rørth M, Sørensen HT.

Clin Epidemiol. 2016 Jun 11;8:195-200. doi: 10.2147/CLEP.S97874. Review.

20.

Suboptimal use of neoadjuvant chemotherapy in radical cystectomy patients: A population-based study.

Schiffmann J, Sun M, Gandaglia G, Tian Z, Popa I, Larcher A, Meskawi M, Briganti A, McCormack M, Shariat SF, Montorsi F, Graefen M, Saad F, Karakiewicz PI.

Can Urol Assoc J. 2016 Mar-Apr;10(3-4):E82-6. doi: 10.5489/cuaj.3292.

Items per page

Supplemental Content

Support Center